Hypoparathyroidism and treatment with recombinant human PTH

References

• Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317–2337.
   Google Scholar
• Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273–2283.
   Google Scholar
• Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101:2300–2312.
   Google Scholar
• Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146:215–222.
   Google Scholar
• Marcucci G, Della Pepa G, Brandi ML. Natpara for the treatment of hypoparathyroidism. Expert Opin Biol Ther. 2016;16:1417–1424.
   Google Scholar
• Natpara package insert. Available from: http://www.accessdata.fda- .gov/drugsatfda_docs/label/2015/125511s000lbl.pdf. [ Last accessed 22 June 2015]
   Google Scholar
• Power ML, Heaney RP, Kalkwarf HJ, et al. The role of calcium in health and disease. Am J Obstet Gynecol. 1999;181:1560–1569.
   Google Scholar
• Bansal B, Bansal M, Bajpai P, et al. Hypocalcemic cardiomyopathy-different mechanisms in adult and pediatric cases. J Clin Endocrinol Metab. 2014;99:2627–2632.
   Google Scholar
• De Sanctis V, Soliman A, Fiscina B. Hypoparathyroidism: from diagnosis to treatment. Curr Opin Endocrinol Diabetes Obes. 2012;19:435–442.
   Google Scholar
• Rubin MR, Sliney J Jr, McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21:1927–1934.
   Google Scholar
• Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23:2018–2024.
   Google Scholar
• Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358–2370.
   Google Scholar
• Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137–144.
   Google Scholar
• Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655–4658.
   Google Scholar
• Rubin MR, Dempster DW, Kohler T, et al. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. 2010;46:190–195.
   Google Scholar
• Cusano NE, Nishiyama KK, Zhang C, et al. Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J Bone Miner Res. 2016;31:308–316.
   Google Scholar
• Cusano NE, Nishiyama KK, Zhang C, et al. Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J Bone Miner Res. 2016;31:308.
   Google Scholar
• Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101:2313–2324.
   Google Scholar
• Underbjerg L, Sikjaer T, Mosekilde L, et al. Postsurgical hypoparathyroidism – risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29:2504–2510.
   Google Scholar
• Underbjerg L, Sikjaer T, Mosekilde L, et al. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30:1738–1744.
   Google Scholar
• Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507–4514.
   Google Scholar
• Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. Jama. 1996;276:631–636.
   Google Scholar
• Winer KK, Yanovski JA, Sarani B, et al. A randomized, crossover trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83:3480–3486.
   Google Scholar
• Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88:4214–4220.
   Google Scholar
• Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008;93:3389–3395.
   Google Scholar
• Winer KK, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95:2680–2688.
   Google Scholar
• Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:391–399.
   Google Scholar
• Winer KK, Fulton K Culter PA and Cutler G. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr. 2014;165:556–563.
   Google Scholar
• Gafni RI, Brahim JS, Andreopoulou P, et al. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res. 2012;27:1811–1820.
   Google Scholar
• Santonati A, Palermo A, Maddaloni E, et al. PTH(1–34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2015;100:3590–3597.
   Google Scholar
• Clarke BL, Kay Berg J, Fox J, et al. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clin Ther. 2014;36:722–736.
   Google Scholar
• Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double blind, placebo-controlled, randomized, phase III study. Lancet. 2013;1:275–283.
   Google Scholar
• Clarke BL, Vokes TJ, Bilezikian JP, et al. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017;55:273–282.
   Google Scholar
• Sikjaer T, Rejnmark L, Thomsen JS, et al. Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study. J Bone Miner Res. 2012;27:781–788.
   Google Scholar
• Sikjaer T, Rolighed L, Hess A, et al. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25:1717–1726.
   Google Scholar
• Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1–84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26:2727–2736.
   Google Scholar
• Rubin MR, Zwahlen A, Dempster DW, et al. Effects of parathyroid hormone administration on bone strength in hypoparathyroidism. Bone Miner Res. 2016;31:1082–1088.
   Google Scholar
• Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99:3694–3699.
   Google Scholar
• Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH(1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98:2356–2361.
   Google Scholar
• Lakatos P, Bajnok L, Lagast H, et al. An open-label extension study of parathyroid hormone rhPTH(1-84) in adults with hypoparathyroidism. Endocr Pract. 2016;22:523–532.
   Google Scholar
• Rubin MR, Cusano NE, Fan WW, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101:2742–2750.
   Google Scholar
• Highlights of prescribing in formation; FORTEO (teriparatide [rDNA origin] injection) for subcutaneous useInitial U.S. Approval: 2002. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021318s012lbl.pdf
   Google Scholar
• Samuels MH, Veldhuis J, Cawley C, et al. Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab. 1993;77:399–403.
   Google Scholar
• Vokes T, Shoback D, Clarke B, et al. Efficacy and safety of low dose recombinant parathyroid hormone (rhPTH[1–84]) in hypoparathyroidism: the RELAY study. Poster presented at: Annual Meeting of American Society for Bone and Mineral Research, October 15, 2012; Minneapolis, MN. Poster MO0412
   Google Scholar
• Cipriani C, Abraham A, Silva BC, et al. Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. Endocrine. 2017;55:591–598.
   Google Scholar
• Bielack SS, Hecker-Nolting S, Blattmann C, et al. Advances in the management of osteosarcoma. F1000Res. 2016;25(5):2767.
   Google Scholar
• Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol. 2006;34:929–940.
   Google Scholar
• Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27:2419–2428.
   Google Scholar
• Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429–2437.
   Google Scholar
• Rubin MR, Manavalan JS, Dempster DW, et al. Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab. 2011;96:176–186.
   Google Scholar
• Tamura T, Noda H, Joyashiki E, et al. Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nat Commun. 2016;18(7):13384.
   Google Scholar